Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome

NCT01200355 | Completed Phase 4 Results

• 1 other identifier: 10-038
• Study Type: interventional
• Target: 113
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to compare the effects, good and/or bad, of posaconazole and micafungin in preventing fungal infections after chemotherapy for acute leukemia or myelodysplastic syndrome. When people take chemotherapy, they are more likely to get infections. Posaconazole has been approved for the prevention of fungal infections in patients who receive induction chemotherapy for acute leukemia and myelodysplastic syndrome. Posaconazole is available only as an oral suspension and has to be given with food. After chemotherapy, many patients are not able to tolerate food or oral medication because of severe mucositis. Patients unable to tolerate food and oral medications cannot take posaconazole. Micafungin is an antifungal medication that is given only intravenously. Micafungin is approved for the treatment of certain fungal infections and for preventing fungal infections in patients who receive bone marrow transplant. The investigators know that micafungin is safe. Micafungin has not been tested for the prevention of fungal infections in patients receiving chemotherapy for acute leukemia and myelodysplastic syndrome. Because micafungin is given by vein, it can be given even in patients who cannot take food or medications by mouth after chemotherapy. In this study the investigators want to compare micafungin to posaconazole when given for the prevention of fungal infections in leukemia and myelodysplastic syndrome patients.

Conditions

Acute Myelogenous Leukemia; Myelodysplastic Syndrome

Keywords

MICAFUNGIN; POSACONAZOLE; antifungal; prolonged neutropenia; 10-038

Outcome Measures

Primary Outcomes (1)

• Time to Failure

  Clinical failure is defined as: 1) need for systemic antifungal therapy (AmBisome) for \> 3 consecutive days for presumptive fungal infection, toxicity or intolerance of study medication or 2) death.

  2 years

Secondary Outcomes (4)

• To Compare the Number of Days on Study Drug Between Patients Who Receive Posaconazole and Patients Who Receive Micafungin.

  2 years

• To Compare the Incidence of Possible, Probable or Proven Invasive Fungal Infections Between Patients Who Receive Posaconazole and Those Who Receive Micafungin During Treatment Phase

  2 years

• Prophylaxis Failure of Study Medication for Any Reason Between Patients Who Receive Posaconazole and Those Who Receive Micafungin.

  2 years

• To Compare Overall Survival Rates at 6 Weeks

  6 weeks from randomization between the two treatment arms.

Study Arms (2)

micafungin

EXPERIMENTAL

This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).

Drug: micafungin

posaconazole

EXPERIMENTAL

This is a single institution (MSKCC), randomized, open-label comparative trial of micafungin and posaconazole administered as prophylaxis against fungal infections during neutropenia following induction chemotherapy for myelogenous leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS).

Drug: posaconazole

Interventions

micafungin DRUG

Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.

micafungin

posaconazole DRUG

Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.

posaconazole

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects of greater than or equal to 18 years of age of either sex and of any race.
• Disease definition:
• Anticipated or documented prolonged neutropenia (ANC\<500/mm3 \[0.5x109/L\]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:
• Intensive induction chemotherapy for new diagnosis of acute myelogenous leukemia, acute lymphocytic leukemia or myelodysplastic syndrome receiving standard anthracycline based chemotherapy
• Re-induction of acute myelogenous or lymphocytic leukemia after primary relapse
• Myelodysplastic syndromes requiring induction (myelosuppressive) chemotherapy
• Female subjects of childbearing potential must have a negative serum pregnancy test as per MSKCC guidelines.
• Able to swallow oral medications

You may not qualify if:

• Subjects with history of presumed or proven invasive fungal infection within 30 days of randomization.
• Subjects who are taking the following:
• Drugs known to interact with posaconazole and that may lead to life-threatening side effects (terfenadine, cisapride, and ebastine at entry or within 24 hours before entry, or astemizole at entry or within 10 days before entry); b. Drugs known to lower the serum concentration/efficacy of posaconazole: cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, and isoniazid at entry or within 24 hours before entry; c. Subjects who are planned to receive \> 2mg flat dose of vinca alkaloids.
• Subjects with a history of hypersensitivity or idiosyncratic reactions to azole agents.
• Subjects with renal insufficiency (estimated creatinine clearance less than 20 mL/minute at baseline or likely to require dialysis during the study).
• Subjects having an electrocardiogram with a prolonged QTc interval by manual reading: QTc greater than 490 msec.
• Subjects with moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase, alanine aminotransferase, or alkaline phosphatase levels greater than 5 times the upper limit of normal (ULN), or a total bilirubin level greater than 3 times the ULN.
• Subjects who are undergoing re-induction chemotherapy and have participated in this study during their first induction chemotherapy.
• Subjects who will be receiving dasatinib.

Sponsors & Collaborators

• Memorial Sloan Kettering Cancer Center: lead
• Astellas Pharma US, Inc.: collaborator

Study Sites (1)

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Related Links

• Memorial Sloan Kettering Cancer Center

MeSH Terms

Conditions

Leukemia, Myeloid, Acute; Myelodysplastic Syndromes

Interventions

Micafungin; posaconazole

Condition Hierarchy (Ancestors)

Leukemia, Myeloid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Bone Marrow Diseases

Intervention Hierarchy (Ancestors)

Lipopeptides; Lipids; Peptides; Amino Acids, Peptides, and Proteins; Echinocandins; Peptides, Cyclic

Results Point of Contact

• Title: Dr. Genovefa Papanicolaou MD
• Organization: Memorial Sloan Kettering Cancer Center

papanicg@mskcc.org

212-639-8361

Study Officials

• Genovefa Papanicolaou, MD

  Memorial Sloan Kettering Cancer Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 9, 2010
• First Posted: September 13, 2010
• Study Start: September 9, 2010
• Primary Completion: April 20, 2017
• Study Completion: April 3, 2018
• Last Updated: May 7, 2018
• Results First Posted: July 24, 2017

Record last verified: 2018-04

Locations

US (1)